Newly Designed Geldanamycin Analogues for Targeted Cancer-Causing Hsp90 Protein Inhibitor: Molecular Docking Study

Abstract:

Cancer is currently a major public health concern worldwide. Previous studies have shown that heat shock protein 90 (Hsp90) is the key common cause of cancer. Thus, Hsp90 is one of the important molecular targets for the development of Hsp90 cancer drug based on geldanamycin (GDM) and alvespimycin (17-DMAG). Herein, novel geldanamycin derivatives, S1-S6 were designed as potential Hsp90 cancer drug by targeting signal transduction pathway, especially against oncogenic client protein from Hsp90. The binding of S1-S6 in the cavity of Hsp90 were investigated by molecular docking using the iGEMDOCK v2.1 software. The results illustrated that S1-S6 bound in the binding site of Hsp90 with similar manner to GDM and 17-DMAG. The binding energies of S1-S6 in Hsp90 (PDB ID:1YET) (-137.49 to -123.24 kcal/mol) were comparable to that of GDM (-133.06 kcal/mol) while the binding energies of S1-S6 in Hsp90 (PDB ID:1OSF) (-137.49 to -131.22 kcal/mol) were slightly higher than that of 17-DMAG (-145.31 kcal/mol). S1-S6 interacted well by hydrogen bonding with key amino acids in the binding site of Hsp90, which could inhibit the cancer cell growth. Therefore, S1-S6 containing novel geldanamycin derivatives could be promising molecules for anti-cancer drug against Hsp90 2 types in the future.

• Periodical: Key Engineering Materials (Volume 914)
• Pages: 111-116
• DOI: https://doi.org/10.4028/p-983h53
• Online since: March 2022
• Authors: Satipat Suttayasorranakhom, Chanjira Jaramornburapong, Waya Phuthawong, Jitnapa Sirirak*
• Keywords: Anti-Cancer Drug, Geldanamycin Analogue, Hsp90 Inhibitor, Molecular Docking

References

[1] P. Anand, A.B. Kunnumakkara, C. Sundaram, K.B. Harikumar, S.T. Tharakan, O.S. Lai, B. Sung, B.B. Aggarwal, Cancer is a preventable disease that requires major lifestyle changes, Pharm. Res., 25(9), 2008, 2097-2116.

DOI: 10.1007/s11095-008-9661-9

[2] C. Chavany, E. Mimnaugh, P. Miller, R. Bitton, P. Nguyen, J. Trepel, L. Whitesell, R. Schnur, J. Moyer, L. Neckers, p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2, J. Biol. Chem., 271, 1996, 4974-4977.

DOI: 10.1074/jbc.271.9.4974

[3] B. Segnitz, U. Gehring, The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin, J. Biol. Chem, 272, 1997, 18694-18701.

DOI: 10.1074/jbc.272.30.18694

[4] P. Miller, C. DiOrio, M. Moyer, R.C. Schnur, A. Bruskin, W. Cullen, J.D. Moyer, Depletion of the erbB-2 gene product p.185 by benzoquinoid ansamycins, Cancer Res., 54, 1994, 2724-2730.

DOI: 10.1006/bbrc.1994.1847

[5] P. Csermely, T. Schnaider, C. Sõti, Z. Prohászka, G. Nardai, The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review, Pharmacol. Ther., 79(2), 1998, 129-168.

DOI: 10.1016/s0163-7258(98)00013-8

[6] J. Buchner, Hsp90 & Co. - a holding for folding, Trends Biochem. Sci., 24, 1999, 136-141.

[7] A.E. Pasqua, B. Wilding, M.D. Cheeseman, K. Jones, Targeting Protein Synthesis, Folding, and Degradation Pathways in Cancer, in: S. Chackalamannil, D. Rotella, S.E. Ward (Eds.), Comprehensive Medicinal Chemistry III, Elsevier, 2017, pp.202-280.

DOI: 10.1016/b978-0-12-409547-2.12395-9

[8] Y. Xiao, Y. Liu, Recent advances in the discovery of novel HSP90 inhibitors: an update from 2014. Curr. Drug Targets, 21(3), 2020, 302-317.

DOI: 10.2174/1389450120666190829162544

[9] E.S. Charles, A.R. Alicia, S. Christine, R. Neal, F.U. Hartl, P.P. Nikola, Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent, Cell, 89, 1997, 239-250.

DOI: 10.1016/s0092-8674(00)80203-2

[10] J.M. Jez, J.C.H. Chen, G. Rastelli, R.M. Strond, D.V. Santi, Crystal structure and molecular modeling of 17-DMAG in complex with human hsp90, Cell Chem. Biol., 10, 2003, 361-368.

DOI: 10.1016/s1074-5521(03)00075-9

[11] K. Lee, J.S. Ryu, Y. Jin, W. Kim, N. Kaur, S.J. Chung, Y. Jeon, J. Park, J.S. Bang, H.S. Lee, T.Y. Kim J.J. Lee, Y.S. Hong, Synthesis and anticancer activity of geldanamycin derivatives derived from biosynthetically generated metabolites. Org. Biomol. Chem., 6(2), 2008, 340-348.

DOI: 10.1039/b713407j

[12] T. Taechowisan, T. Samsawat, W. Puckdee, W.S. Phutdhawong, Cytotoxicity activity of geldanamycin derivatives against various cancer cell lines, J. Appl. Pharm. Sci., 10(06), 2020, 12-21.

DOI: 10.7324/japs.2020.10603

[13] N. Skrzypczak, K. Pyta, P. Ruszkowski, P. Mikołajczak, M. Kucińska, M. Murias, M. Gdanieca, F. Bartl, P. Przybylski, Anticancer activity and toxicity of new quaternary ammonium geldanamycin derivative salts and their mixtures with potentiators, J. Enzyme Inhib. Med. Chem., 36(1), 2021, 1898-1904.

DOI: 10.1080/14756366.2021.1960829

[14] L. Neckers, Hsp90 inhibitors as novel cancer chemotherapeutic agents, Trends Mol. Med., 8(4), 2002, S55-S61.

DOI: 10.1016/s1471-4914(02)02316-x

[15] Z. Guo, Y. Xu, Y. Peng, H. ur Rashid, W. Quan, P. Xie, W. Lichuan, J. Jiang, L. Wang, X. Liu, Design, synthesis and evaluation of novel (S)-tryptamine derivatives containing an allyl group and an aryl sulfonamide unit as anticancer agents, Bioorg. Med. Chem. Lett., 29(9), 2019, 1133-1137.

DOI: 10.1016/j.bmcl.2019.02.023

[16] S. Kousara, S.N. Anjuma, F. Jaleela, J. Khana, S. Naseema, Biomedical significance of tryptamine: a review, J. Pharmacovigil, 2017, 5(5), 239.

DOI: 10.4172/2329-6887.1000239